Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 33 HER2-positive Breast Cancer 8 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 3 Advanced Breast Cancer 3 Breast Diseases 2 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 HER2-positive Early Breast Cancer 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2 Positive Metastatic Breast Cancer 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Estrogen Receptor-positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Digestive System Tumor 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡